Gibson Oncology
Private Company
Funding information not available
Overview
Gibson Oncology is a private, pre-revenue biotech founded in 2018, headquartered in Nashville, TN, with a significant operational presence in Miami, FL. Its lead asset, LMP744, has received FDA Orphan Drug Designation for glioblastoma and is entering a Phase II trial in collaboration with the NIH, leveraging its unique dual Top1/cMYC inhibition and ability to cross the blood-brain barrier. The company's broader pipeline includes additional licensed compounds (LMP400, LMP776) and an internally discovered oral class of Aza Indenoisoquinolines, targeting homologous recombination deficient cancers and offering potential synergy with PARP inhibitors.
Technology Platform
Non-camptothecin topoisomerase I (Top1) inhibitors (indenoisoquinolines and Aza analogues) with dual Top1/cMYC inhibition, blood-brain barrier penetration, and selective activity in homologous recombination deficient (HRD) and SLFN11+ cancers.
Opportunities
Risk Factors
Competitive Landscape
The glioblastoma space is competitive with numerous approaches (e.g., targeted therapies, immunotherapies, tumor-treating fields), though effective options remain limited. Gibson's non-camptothecin Top1 inhibitors with BBB penetration represent a differentiated mechanism, but they compete with other DNA-damaging agents and emerging targeted therapies.